B2-DNR

B2-DNR is an autologous, nanobody-based chimeric antigen receptor (CAR) T-cell therapy designed to target Delta-like ligand 3 (DLL3), a protein highly expressed in small-cell lung cancer (SCLC). The therapy utilizes a biparatopic CAR construct (B2) derived from camelid-immunized phage display libraries, which provides high specificity and affinity for DLL3 without cross-reactivity to other Notch ligands. To overcome the immunosuppressive tumor microenvironment, B2-DNR is 'armored' with a dominant-negative TGFβ receptor II (DNR), which blocks TGFβ-driven signaling and enhances T-cell persistence and antitumor activity. B2-DNR is manufactured using the proprietary 3-day FasTCAR process, which aims to produce T cells with superior fitness and durability compared to conventional manufacturing methods. Preclinical data indicate that B2-DNR can rapidly clear both high and low DLL3-expressing tumors with a favorable safety profile.

Other names

DLL3-targeted FAST-CAR T-cell therapyDLL-3-targeted FAST-CAR T-cell therapyDLL 3-targeted FAST-CAR T-cell therapyB2-DNR CAR TB-2-DNR CAR TB 2-DNR CAR T